MRUS
Merus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MRUS Profile
Merus N.V.
A clinical-stage oncology company that developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®)
Uppsalalaan 17, 3584 CT Utrecht, The Netherlands
--
Merus N.V. was established under Dutch law on June 16, 2003. The company is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapies. Its pipeline of full-length human bispecific antibody candidates, which they call biclonics, is generated from their technology platform.
